Skip to content
type1.science
Phase 2Active, not recruitingNCT04589325

I-DIT: ixekizumab anti-IL-17 in new-onset T1D

Swedish randomized phase 2 trial testing ixekizumab, an anti-IL-17A antibody used in psoriasis, for preservation of residual insulin secretion in adults with new-onset T1D.

Primary endpoints

  • Residual insulin secretion

Results so far

No results posted yet.